FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review ImmunityBio’s resubmission of its Biologics License Application (BLA) for N-803, a…
Read More...
Read More...
